Free Trial

Integer Holdings Co. (NYSE:ITGR) Given Average Recommendation of "Moderate Buy" by Analysts

Integer logo with Medical background
Remove Ads

Shares of Integer Holdings Co. (NYSE:ITGR - Get Free Report) have received a consensus rating of "Moderate Buy" from the nine ratings firms that are presently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $148.56.

Several research firms recently weighed in on ITGR. Oppenheimer lowered Integer from an "outperform" rating to a "market perform" rating in a report on Friday, February 21st. Benchmark boosted their price objective on Integer from $140.00 to $150.00 and gave the company a "buy" rating in a report on Friday, February 21st. Raymond James started coverage on Integer in a research note on Friday, March 28th. They issued an "outperform" rating and a $145.00 target price on the stock. Truist Financial boosted their target price on shares of Integer from $147.00 to $163.00 and gave the company a "buy" rating in a research note on Wednesday, December 11th. Finally, Citigroup raised their price target on shares of Integer from $130.00 to $145.00 and gave the stock a "neutral" rating in a research note on Wednesday, December 11th.

Read Our Latest Report on ITGR

Integer Stock Performance

NYSE ITGR traded down $2.53 during trading hours on Friday, hitting $113.84. 753,579 shares of the company's stock traded hands, compared to its average volume of 339,809. The company has a current ratio of 2.95, a quick ratio of 2.09 and a debt-to-equity ratio of 0.62. Integer has a 52 week low of $104.93 and a 52 week high of $146.36. The firm has a market capitalization of $3.83 billion, a P/E ratio of 33.88, a P/E/G ratio of 1.72 and a beta of 1.09. The business's fifty day moving average price is $124.34 and its two-hundred day moving average price is $131.00.

Remove Ads

Integer (NYSE:ITGR - Get Free Report) last released its earnings results on Thursday, February 20th. The medical equipment provider reported $1.43 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.46 by ($0.03). The firm had revenue of $449.50 million during the quarter, compared to analysts' expectations of $446.28 million. Integer had a return on equity of 11.65% and a net margin of 6.92%. Equities research analysts predict that Integer will post 6.01 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Mather Group LLC. boosted its stake in shares of Integer by 304.3% during the fourth quarter. Mather Group LLC. now owns 190 shares of the medical equipment provider's stock valued at $25,000 after purchasing an additional 143 shares in the last quarter. Lee Danner & Bass Inc. purchased a new stake in Integer during the fourth quarter worth $27,000. AdvisorNet Financial Inc bought a new stake in Integer during the 1st quarter valued at $28,000. R Squared Ltd purchased a new position in shares of Integer in the 4th quarter valued at $44,000. Finally, Sterling Capital Management LLC raised its position in shares of Integer by 472.9% in the 4th quarter. Sterling Capital Management LLC now owns 338 shares of the medical equipment provider's stock worth $45,000 after acquiring an additional 279 shares in the last quarter. Hedge funds and other institutional investors own 99.29% of the company's stock.

About Integer

(Get Free Report

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.

Featured Stories

Analyst Recommendations for Integer (NYSE:ITGR)

Should You Invest $1,000 in Integer Right Now?

Before you consider Integer, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Integer wasn't on the list.

While Integer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

5 Stocks to BUY Now as Tariff Uncertainty Fades
WWE Stock Could Explode Next Week — Now’s the Time to Buy Into TKO
These 3 Dividend Stocks Might Be the Safest Bet Right Now

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads